Cybin is trading 10.68% up at $11.87 on October 9, 2026, with no clear company-specific announcement explaining the move. - The latest company news is an October 8 notice about an investor presentation scheduled for October 21, not a new clinical result or major event. - Biotech-sector strength may be contributing: XBI is up 2.50%, amid positive sentiment around IPOs and dealmaking. This is supporting context, not a confirmed direct catalyst for Cybin’s larger gain.